Shu-Jun Jiang1, Hui Dong1, Jing-Bin Li1, Li-Jun Xu1, Xin Zou1, Kai-Fu Wang1, Fu-Er Lu1, Ping Yi1. 1. Shu-Jun Jiang, Hui Dong, Li-Jun Xu, Xin Zou, Kai-Fu Wang, Fu-Er Lu, Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Abstract
AIM: To investigate the molecular mechanisms of berberine inhibition of hepatic gluconeogenesis in a diabetic rat model. METHODS: The 40 rats were randomly divided into five groups. One group was selected as the normal group. In the remaining groups (n = 8 each), the rats were fed on a high-fat diet for 1 mo and received intravenous injection of streptozotocin for induction of the diabetic models. Berberine (156 mg/kg per day) (berberine group) or metformin (184 mg/kg per day) (metformin group) was intragastrically administered to the diabetic rats and 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside (AICAR) (0.5 mg/kg per day) (AICAR group) was subcutaneously injected to the diabetic rats for 12 wk. The remaining eight diabetic rats served as the model group. Fasting plasma glucose and insulin levels as well as lipid profile were tested. The expressions of proteins were examined by western blotting. The nuclear translocation of CREB-regulated transcription co-activator (TORC)2 was observed by immunohistochemical staining. RESULTS: Berberine improved impaired glucose tolerance and decreased plasma hyperlipidemia. Moreover, berberine decreased fasting plasma insulin and homeostasis model assessment of insulin resistance (HOMA-IR). Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK). The level of phophorylated TORC2 (p-TORC2) protein in the cytoplasm was higher in the berberine group than in the model group, and no significant difference in total TORC2 protein level was observed. Immunohistochemical staining revealed that more TORC2 was localized in the cytoplasm of the berberine group than in the model group. Moreover, berberine treatment downregulated protein expression of the key gluconeogenic enzymes (phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) in the liver tissues. CONCLUSION: Our findings revealed that berberine inhibited hepatic gluconeogenesis via the regulation of the LKB1-AMPK-TORC2 signaling pathway.
AIM: To investigate the molecular mechanisms of berberine inhibition of hepatic gluconeogenesis in a diabeticrat model. METHODS: The 40 rats were randomly divided into five groups. One group was selected as the normal group. In the remaining groups (n = 8 each), the rats were fed on a high-fat diet for 1 mo and received intravenous injection of streptozotocin for induction of the diabetic models. Berberine (156 mg/kg per day) (berberine group) or metformin (184 mg/kg per day) (metformin group) was intragastrically administered to the diabeticrats and 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside (AICAR) (0.5 mg/kg per day) (AICAR group) was subcutaneously injected to the diabeticrats for 12 wk. The remaining eight diabeticrats served as the model group. Fasting plasma glucose and insulin levels as well as lipid profile were tested. The expressions of proteins were examined by western blotting. The nuclear translocation of CREB-regulated transcription co-activator (TORC)2 was observed by immunohistochemical staining. RESULTS:Berberine improved impaired glucose tolerance and decreased plasma hyperlipidemia. Moreover, berberine decreased fasting plasma insulin and homeostasis model assessment of insulin resistance (HOMA-IR). Berberine upregulated protein expression of liver kinase (LK)B1, AMP-activated protein kinase (AMPK) and phosphorylated AMPK (p-AMPK). The level of phophorylated TORC2 (p-TORC2) protein in the cytoplasm was higher in the berberine group than in the model group, and no significant difference in total TORC2 protein level was observed. Immunohistochemical staining revealed that more TORC2 was localized in the cytoplasm of the berberine group than in the model group. Moreover, berberine treatment downregulated protein expression of the key gluconeogenic enzymes (phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) in the liver tissues. CONCLUSION: Our findings revealed that berberine inhibited hepatic gluconeogenesis via the regulation of the LKB1-AMPK-TORC2 signaling pathway.
Authors: Reuben J Shaw; Katja A Lamia; Debbie Vasquez; Seung-Hoi Koo; Nabeel Bardeesy; Ronald A Depinho; Marc Montminy; Lewis C Cantley Journal: Science Date: 2005-11-24 Impact factor: 47.728
Authors: J C Yoon; P Puigserver; G Chen; J Donovan; Z Wu; J Rhee; G Adelmant; J Stafford; C R Kahn; D K Granner; C B Newgard; B M Spiegelman Journal: Nature Date: 2001-09-13 Impact factor: 49.962
Authors: Jiandie Lin; Pei-Hsuan Wu; Paul T Tarr; Katrin S Lindenberg; Julie St-Pierre; Chen-Yu Zhang; Vamsi K Mootha; Sibylle Jäger; Claudia R Vianna; Richard M Reznick; Libin Cui; Monia Manieri; Mi X Donovan; Zhidan Wu; Marcus P Cooper; Melina C Fan; Lindsay M Rohas; Ann Marie Zavacki; Saverio Cinti; Gerald I Shulman; Bradford B Lowell; Dimitri Krainc; Bruce M Spiegelman Journal: Cell Date: 2004-10-01 Impact factor: 41.582
Authors: Daniel E Lefever; Joella Xu; Yingjia Chen; Guannan Huang; Nagy Tamas; Tai L Guo Journal: Toxicol Appl Pharmacol Date: 2016-05-21 Impact factor: 4.219